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Abstract
Maximizing positive outcomes for serious Gram-positive infections, such as those caused by Staphylococcus species, requires an aggres-
sive treatment approach. Although speciﬁc approaches will depend upon many factors, the underlying common strategy should recog-
nize the positive contribution of minimizing complications and inpatient treatment duration and the efﬁcient use of healthcare
resources, while also focusing on rapid resolution of infection and safety and tolerability. To advance the standard of care for patients,
we need to utilize therapies that enable such a range of factors to be improved. Treatment guidelines are useful to establish evidence-
based standards of care, but they are updated infrequently and there is currently no pan-European consensus for the treatment of
staphylococcal infections. With the beneﬁt of the clinical experience that has been acquired for the most recently licensed antibiotics,
together with an appreciation of the appropriate usage of older agents, there are good prospects for achieving positive outcomes earlier
and in a greater range of patients with staphylococcal infections, and treatment guidelines should be updated regularly to reﬂect this.
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Introduction
Despite recent advances, Gram-positive infections remain a
signiﬁcant cause of morbidity and mortality among hospital-
ized patients and are the cause of various serious hospital-
acquired and community-acquired infections [1]. In order to
maximize positive outcomes for patients, aggressive treat-
ment approaches against the opportunistic pathogens that
are the major causative agents of these infections are
required. Of particular note for its pathogenicity is Staphylo-
coccus aureus, methicillin-resistant strains of which have
become more prevalent in some countries and are associ-
ated with greater morbidity and mortality than wild-type
strains [2].
The past decade has witnessed signiﬁcant changes in the
proﬁles of susceptibility of Gram-positive bacteria to vanco-
mycin, a traditional treatment of choice for serious infections
caused by methicillin-resistant S. aureus (MRSA). These
include the emergence of vancomycin-resistant staphylococci
and enterococci, as well as vancomycin-intermediate
S. aureus and heteroresistant vancomycin-intermediate
S. aureus [3,4]. Furthermore, several reports indicate that
the MICs of vancomycin for susceptible strains have
increased over time in some healthcare institutions [5–8],
and that this has had a negative impact on the clinical out-
comes for patients [9–11]. This changing epidemiology serves
to emphasize the difﬁculty of ensuring that patients receive
appropriate antibiotic therapy.
Speciﬁc treatment approaches to staphylococcal infec-
tions will depend upon many factors, including the species,
strain and site of infection, as well as the presence of any
co-morbid conditions. However, the underlying common
strategy should recognize universal goals of treatment that
include minimizing the risk of complications experienced
during prolonged infection, minimizing time spent in hospi-
tal and optimizing the use of limited healthcare resources.
Therefore, the ideal antibiotic will resolve infection rapidly
and completely, and will have a good safety and tolerability
proﬁle and a convenient dosing regimen. Each of these
key features will be discussed in further depth in this
review.
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Minimizing Complications in
Staphylococcal Infections
If not treated effectively and rapidly, patients with Gram-
positive infections are at risk of developing serious complica-
tions. In a recent surveillance programme in Scotland, hospi-
tal-acquired infections contributed to mortality in 13% of all
deaths [12]. Surgical site infections (SSIs) are some of the
most frequent nosocomial Gram-positive infections, with
incidence rates of up to 18%, even after clean surgery [13].
S. aureus continues to be a major cause of SSIs, being
responsible for nearly 45% of orthopaedic-related SSIs in the
UK between 2004 and 2007, with 62% of these being caused
by MRSA [14]. A review of 3254 deaths of patients in all
specialties of surgical care in Scotland during 2006 found that
in 7% of the deaths that followed surgery, infection had
developed at the operation site, and that 4% of all patients
had hospital-acquired MRSA at the time of death [12].
Therefore, it would appear that effective management of
these infections continues to be a signiﬁcant challenge.
New antibiotics are continuously being developed, particu-
larly for staphylococcal infections resistant to semi-synthetic
penicillins. In light of the increasing number of available anti-
biotic agents, continuous reappraisal of treatment options is
necessary to ensure that patients beneﬁt maximally from
these pharmaceutical advances; antibiotic agents with alterna-
tive modes of action may warrant particular consideration.
Daptomycin (Cubicin) is the ﬁrst available agent from a new
class of antibiotics, the cyclic lipopeptides. The efﬁcacy of
daptomycin for patients with complicated skin and soft tissue
infections (cSSTIs) was compared with that of conventionally
recommended antibiotics (penicillinase-resistant penicillins or
vancomycin) [15]. Response rates were similar among
treatment groups, across all baseline diagnoses, with overall
success rates of 83.4% and 84.2% for the daptomycin and
comparator groups, respectively [15].
Bloodstream infections (BSIs) constitute a potential com-
plication of many peripheral infections, including SSIs, and
represent a route by which these can give rise to numer-
ous serious complications, which may be localized, such as
infective endocarditis (IE), infections of bones, joints or
implanted devices, myositis, epidural abscess or meningitis,
or systemic, such as systemic inﬂammatory response syn-
drome [16,17]. For patients with BSIs, MRSA and time to
culture positivity (a surrogate marker for the size of the
inoculum) have been reported as independent predictors of
death [18]. Thus, BSIs are justiﬁably considered to be a
medical emergency, especially when S. aureus is the sus-
pected pathogen.
For many years, semi-synthetic penicillins and vancomycin
have been the pillars of treatment for S. aureus BSIs. For
methicillin-sensitive S. aureus (MSSA), the greater efﬁcacy of
b-lactams relative to vancomycin is well documented, despite
the susceptibility of MSSA to vancomycin in vitro [19–22].
For example, in a multicentre, prospective observational
study of 505 consecutive patients with S. aureus bacteraemia
(SAB), nafcillin proved superior to vancomycin for the treat-
ment of MSSA. Furthermore, therapy with vancomycin was
signiﬁcantly associated with relapse of infection [19]. One of
the key strengths of vancomycin has been in the treatment
of MRSA infections, although data now support a more
sophisticated approach to its choice than reliance on a posi-
tive susceptibility test. Recent reports suggest that the efﬁ-
cacy of vancomycin against MRSA strains with a vancomycin
MIC of ‡1.5 mg/L may be compromised [11,23]. Therefore,
although vancomycin remains an effective treatment for many
Gram-positive infections, clinicians may need to consider
alternatives when the methicillin status of a suspected
S. aureus infection is uncertain or when susceptible MRSA
strains with vancomycin MICs at the upper end of the sus-
ceptible range have been identiﬁed or are suspected on the
basis of local epidemiology. Daptomycin, as an alternative to
these standard therapies, has demonstrated efﬁcacy in com-
plicated and uncomplicated SABs as well as right-sided IE in
a recent study, despite there being few relevant patients for
this speciﬁc indication (Fig. 1) [24]. In this study, daptomycin
was proven to be effective against both MSSA and MRSA,
and as such, may theoretically be advantageous over cur-
rently licensed agents for the empirical treatment of Gram-
positive infections.
Rapid Resolution of Infection
In order to maximize patient beneﬁt, the optimal treatment
regimen should ensure the prompt administration of an
appropriate antibiotic agent. However, a survey of physicians
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FIG. 1. Daptomycin success against Staphylococcus aureus bactera-
emia and infective endocarditis (IE) in a phase III trial [24].
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(n = 605) from the European G5 countries (France, Ger-
many, the UK, Italy and Spain) revealed that c. 50% of
patients with MRSA receive inappropriate ﬁrst-line therapy
[25]. Patients receiving delayed or inappropriate therapy are
at increased risk of mortality [26,27]. Lodise et al. [26] found
that delayed treatment was an independent predictor of infec-
tion-related mortality (OR 3.8; 95% CI 1.3–11.0; p =0.01)
and was associated with a longer hospital stay than early
treatment (20.2 days vs. 14.3 days; p =0.05) for patients with
hospital-acquired SAB. Similarly, in a different study, a statisti-
cally signiﬁcant relationship was found between the rates of
inadequate antimicrobial therapy and associated mortality,
with reported mortality rates of 62% vs. 28% for patients
receiving inadequate vs. adequate therapy, respectively
(p <0.001) [27]. Ideally, in addition to its prompt administra-
tion, an appropriate antibiotic agent should have a rapid onset
of action and reliably deliver therapeutic serum concentra-
tions after administration of the ﬁrst dose. Therefore,
appraisal of the antibiotic options for any patient should
include consideration of their pharmacokinetic and pharma-
codynamic proﬁles.
Optimal dosing of glycopeptides is achieved by therapeutic
drug monitoring and/or loading doses. The typical dose of
vancomycin (1 g every 12 h, intravenously) achieves trough
serum concentrations of 5–10 mg/L [28,29]; however, a
study in patients with bacteraemia concluded that patients
were more likely to become afebrile within 72 h if vancomy-
cin trough concentrations were ‡10 mg/L [30]. It is typically
recommended that vancomycin dosing is adjusted to achieve
trough levels of 10–15 mg/L. Achieving therapeutic serum
concentrations with teicoplanin may also require dosing
adjustments. Pharmacokinetic analysis has predicted that
therapeutic trough levels of ‡10 mg/L are achieved after
4 days of administration [31]. In clinical practice, steady state
is achieved slowly and requires in excess of 14 days of
repeated administration for 93% of patients [32]. Therefore,
loading doses (6 mg/kg every 12 h for at least three doses)
are recommended as part of the standard dosing for patients
with moderate and severe infections [31], and such doses
are considered mandatory in all critically ill patients [33].
High loading doses may reduce the delay in attaining thera-
peutic concentrations; monitoring of teicoplanin serum con-
centrations might be helpful in certain patient groups to
ensure that therapeutic concentrations are achieved [32]. In
fact, the British Society for Antimicrobial Chemotherapy rec-
ommend therapeutic drug monitoring for patients with seri-
ous infections who are treated with teicoplanin [34].
Although there are different doses for the two indications
of daptomycin, therapeutic drug monitoring is not required
[35]. After multiple doses, plasma daptomycin concentrations
remain consistent and predictable, with only small increases
in peak plasma concentration and area under the plasma
concentration–time curve values being noted from the ﬁrst
dose to the achievement of steady state (Fig. 2) [36]. With
respect to pharmacodynamics, in vitro analysis of simulated
endocardial vegetations has shown that daptomycin is rapidly
bactericidal against both MSSA and MRSA after 24 h
(decrease of 5.51 to 6.31 ± 0.10 log10 CFU/g), whereas nei-
ther vancomycin nor linezolid exhibited bactericidal activity
throughout the 72-h experiment [37]. These results were
corroborated in an in vivo animal model, in which daptomycin
showed greater and more rapid bactericidal activity against
MSSA than nafcillin or linezolid and against MRSA than
vancomycin or linezolid (Fig. 3) [38]. In clinical trials, a rapid
response was observed with daptomycin therapy in patients
with cSSTIs. A greater proportion of daptomycin-treated
patients than patients treated with conventional antibiotics
achieved clinical success within the ﬁrst 4–7 days of therapy
(63% vs. 33%, respectively; p <0.001) [39].
Pharmacokinetic–pharmacodynamic factors that may inﬂu-
ence the rapidity of infection resolution may be tissue
speciﬁc. For example, daptomycin interacts with and is inhib-
ited by pulmonary surfactant, which renders it ineffective for
simple bronchoalveolar pneumonia [40]. By contrast, the
pharmacokinetic proﬁle of linezolid makes it particularly suit-
able for the treatment of pneumonia. Linezolid has long
plasma and intrapulmonary half-lives, and after a twice-daily
600-mg dose, the concentration of linezolid in both plasma
and pulmonary epithelial lining ﬂuid exceeds the susceptibility
breakpoint for Gram-positive bacteria [41,42].
Minimizing Inpatient Treatment Duration
It is generally recognized that returning the patient to the
community at the earliest possible time is not only beneﬁcial
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FIG. 2. Daptomycin plasma drug concentration over time for once-
daily dosing of the 30-min intravenous infusion, adapted from reference
[36], with permission from the American Society for Microbiology.
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for the patient, but will also reduce the pressure on limited
hospital resources. With the total annual cost of treating
nosocomial MRSA BSIs in Europe estimated at €117 million
(Verhoef et al. http://www.scoreproject.org/SCORE_me-
t_ISBN.pdf), health economics is an increasingly important
component of healthcare protocols. Direct drug costs con-
tribute only a fraction of the overall treatment costs. Treat-
ment with antimicrobials that have extended infusion
periods, require therapeutic drug monitoring or have a slow
onset of action may serve to prolong the duration of hospi-
talization for the patient, thereby impacting on the total
costs of treatment [43]. Moreover, a longer hospital stay
increases the risks of both nosocomial infection and trans-
mission of infection to other hospitalized patients [44].
Evaluation of economic outcomes has indicated that dapto-
mycin is more cost-effective than vancomycin in the treatment
of cSSTIs [39]. As compared with patients treated with vanco-
mycin, daptomycin-treated patients achieved a more rapid res-
olution of symptoms within 3 days (90% vs. 70%; p <0.01), and
a greater proportion experienced clinical improvement (98%
vs. 81%; p <0.01) within 5 days. Treatment with daptomycin
was also associated with a shorter duration of intravenous
therapy (median, 4 days vs. 7 days; p <0.001) and antibiotic-
related hospitalization (median, 4 days vs. 8 days; p <0.001)
than treatment with vancomycin. The total cost of hospitaliza-
tion was signiﬁcantly reduced in the daptomycin-treated
group as compared with the vancomycin-treated group
(median, US$ 5027 vs. US$ 7552; p <0.01).
One obvious way to reduce the duration of hospital stays is
for antimicrobial therapy to be administered in an outpatient
setting, and agents with oral administration may be particularly
advantageous for some patients. Linezolid is available as both
intravenously and orally administered formulations. The oral
formulation of linezolid maintains 100% bioavailability, which
means that patients can be switched from inpatient to outpa-
tient therapy without the need for dosage adjustment [45,46].
Clinical studies suggest that outpatient treatment with oral lin-
ezolid is both efﬁcacious and cost-effective [47,48].
Notwithstanding the beneﬁts of orally administered anti-
microbial agents, outpatient parenteral antimicrobial therapy
(OPAT) is increasingly an option for patients with non-seri-
ous infections who are medically stable and whose infections
are responding to treatment. Parenteral administration rap-
idly achieves peak serum concentrations, and administration
by a healthcare professional, either in the community or in
an outpatient setting, might facilitate compliance, thereby
potentially reducing the risk of the emergence of resistant
strains. The potential for relapse of infection or for the
spread of infection to the community are also reduced if
compliance is ensured. Key attributes of antimicrobial agents
considered for OPAT include proven efﬁcacy and a good
safety and tolerability proﬁle, as well as a long half-life, so
that they require infrequent administration. Antimicrobial
agents with a short administration time and no requirement
for therapeutic dose monitoring may also be advantageous
for use in an ambulatory setting.
Teicoplanin may be particularly suitable for outpatient
administration, owing to its once-daily intramuscular injec-
tion, and as such has been one of the most frequently
selected antibiotic agents for European OPAT programmes
[49,50]. Experience of OPAT with daptomycin is increasing,
and the evidence to date suggests that it is both safe and
effective for use as OPAT in patients with Gram-positive
infections. Analysis of data from the Cubicin Outcomes Reg-
istry and Experience (CORE)—a US retrospective post-mar-
keting database of daptomycin-treated patients—showed a
FIG. 3. In vivo activity of daptomycin, vanco-
mycin and nafcillin against methicillin-resistant
Staphylococcus aureus (MRSA) peritonitis in
healthy rats. Luminescent images of MRSA
(Xen-1) peritonitis in healthy rats. Groups of
mice (n = 5/group) were anaesthetized with
isoﬂurane and imaged for 3 min at 0, 2 and
4 h after being dosed with 10 mL/kg saline,
50 mg/kg daptomycin, 100 mg/kg vancomycin
or 100 mg/kg nafcillin. Reproduced from refer-
ence [38], with permission from the American
Society for Microbiology.
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higher rate of clinical success for OPAT patients than for
those receiving daptomycin on an inpatient basis (94.6% vs.
86.3%, respectively; p <0.001). However, this difference may
be attributable to differences in the baseline characteristics
of the two groups, as OPAT patients were younger and had
fewer underlying diseases than inpatients. There was no sig-
niﬁcant difference in the occurrence of daptomycin-related
adverse events between the two groups (5.8% and 8.3% for
the OPAT and inpatient groups, respectively; p =0.12) [51].
A recent analysis has suggested that daptomycin might be
an appropriate treatment option for patients with SAB/IE
completing their therapy in the outpatient setting. Outcomes
for patients treated as part of a randomized trial that
compared daptomycin with standard therapy (semi-synthetic
penicillin or vancomycin, each with 4 days of concomitant
low-dose gentamicin) [24] were assessed according to treat-
ment setting. Patients who received a portion of their antimi-
crobial treatment outside of the hospital had a higher rate of
clinical success at the test-of-cure visit than those who com-
pleted their full course of therapy as inpatients (86.4% vs.
55.7%; p <0.001). Within the OPAT group, clinical success
rates were reported to be similar for patients treated with
daptomycin and those treated with standard therapy (90%
and 83%, respectively). Persistent infection and relapse were
less frequent in the OPAT group than in the inpatient group,
and OPAT was associated with fewer deaths than inpatient
treatment (3.9% vs. 18.6%; p =0.001) [52].
A randomized phase I study assessed the safety and tolera-
bility of daptomycin administered as a 2-min intravenous injec-
tion [53]. The daptomycin 2-min intravenous injection was
well tolerated, with no serious or severe adverse events after
administration of either a single dose or once-daily injections
of both 4 and 6 mg/kg for a period of seven consecutive days.
No clinically signiﬁcant differences in pharmacokinetic parame-
ters were observed when daptomycin was administered as a
single 2-min intravenous injection as opposed to the standard
30-min intravenous infusion. The daptomycin 2-min intrave-
nous injection has been submitted for regulatory review, and
the results of this study suggest that it might be particularly
suitable for use in the outpatient setting.
Maximizing Safety and Tolerability
For any given treatment regimen, the safety and tolerability
of administered agents are of paramount importance. This is
brought more sharply into focus with critically ill patients,
such as those in an intensive-care unit, who may have co-
morbid conditions, or for patients with renal insufﬁciency.
Aside from their potential for inducing hypersensitivity reac-
tions, b-lactams are generally regarded as some of the best-
tolerated antibiotics. Vancomycin is dose-limited by the risk
of nephrotoxicity, which can be managed by therapeutic dose
monitoring and dose reductions for patients with renal
impairment. The safety and tolerability of daptomycin have
been compared with these standards of care (initial low-dose
gentamicin in combination with either an anti-staphylococcal
penicillin or vancomycin) in two phase III studies in patients
with cSSTIs [15] as well as in patients with SAB/IE [24]. In all
three studies, the overall incidence of adverse events after
treatment with daptomycin or comparator antibiotics was
found to be similar. Furthermore, the majority of adverse
events after daptomycin treatment were judged to be unre-
lated to the study treatment and were of mild to moderate
severity. Although increases in plasma creatine phosphoki-
nase (CPK) were noted in daptomycin phase I studies [35],
close monitoring of CPK in the cSSTI study, which included
more than 1000 patients, revealed no clinically or statistically
signiﬁcant differences in the distribution of CPK values at
baseline or throughout the study duration [15]. In the SAB/IE
study, creatinine kinase elevations were signiﬁcantly more
frequently observed in the daptomycin group than in the
standard therapy group (6.7% vs. 0.9%, respectively;
p =0.04). Signiﬁcantly fewer daptomycin-treated patients
experienced renal impairment than those in the comparator
group (6.7% vs. 18.1%, respectively; p =0.009) [24]. In the
USA, no dose adjustments are required when prescribing
daptomycin for patients with mild to moderate renal impair-
ment [54]. In Europe, dose adjustments are not required for
patients with mild to moderate renal impairment (creatinine
clearance (CrCl) ‡30 mL/min) who are being treated for
cSSTIs without SAB [35]. No recommendations have been
made regarding dose reductions of daptomycin for patients
with right-sided IE or cSSTIs associated with SAB, and its use
in these indications for patients with CrCl <50 mL/min must
be justiﬁed by clinical beneﬁt outweighing the potential
risk. For cSSTI patients with severe renal impairment
(CrCl <30 mL/min), it is recommended that the dosing
frequency of daptomycin be extended to every 48 h.
Implementation of Therapeutic Advances
Treatment guidelines are important for the establishment of
evidence-based standards of care. However, many guidelines
are updated infrequently and are often focused on prophylaxis
or may be diagnosis-speciﬁc. Moreover, many are country-spe-
ciﬁc, and there is currently no pan-European consensus for the
treatment of staphylococcal infections. In light of the changing
epidemiology and the continued introduction of newer antimi-
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crobial agents, regular reviews of treatment guidelines become
of increasing importance. A recent publication has provided
the rationale for the inclusion of daptomycin in guidelines for
the treatment of bacterial IE caused by staphylococci. It is of
note that the importance of bactericidal activity for effective
treatment of IE is recognized [55].
Summary and Conclusions
Prompt treatment that provides appropriate empirical cover-
age with rapidly acting bactericidal agents that promptly and
reliably reach therapeutic concentrations will assist in achiev-
ing rapid recovery from infection with minimal complications,
while ensuring the cost-effectiveness of healthcare provision.
Newer antibiotics might have both the potency required for
the effective treatment of staphylococcal infections with
reduced susceptibility to the current standard of care and
the option of outpatient administration. Clear, evidence-
based treatment guidelines, up to date with regard to
licensed agents and epidemiological developments, will facili-
tate the implementation of treatment protocols that have
the potential to maximize outcomes for patients with staphy-
lococcal infections.
Acknowledgements
Editorial and writing support for the author of this article
was provided by R. Laylor of Chameleon Communications
International with Novartis Pharma AG sponsorship. This
article is published as part of a supplement entitled ‘Optimiz-
ing outcomes in patients with serious Gram-positive
infections’, sponsored by a medical grant from Novartis, and
has been derived from a symposium entitled ‘Positive out-
comes in Gram-positive infections’ that was held at the 18th
European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID), April 2008.
Transparency Declaration
J.-P. Stahl is a member of the Daptomycin International Advi-
sory Board.
References
1. Bryant KA, Woods CR. Healthcare-acquired infections due to Gram-
positive bacteria. Pediatr Infect Dis J 2008; 27: 455–456.
2. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphy-
lococcus aureus. Clin Infect Dis 2008; 46 (suppl 5): S344–S349.
3. Centers for Disease Control and Prevention. Vancomycin-resistant
Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb Mortal Wkly
Rep 2002; 51: 565–567.
4. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese
hospitals of strains of Staphylococcus aureus heterogeneously resistant
to vancomycin. Lancet 1997; 350: 1670–1673.
5. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-
vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-
susceptible clinical methicillin-resistant S. aureus (MRSA) blood iso-
lates from 2001–05. J Antimicrob Chemother 2007; 60: 788–794.
6. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin
MICs for Staphylococcus aureus clinical isolates from a university hos-
pital during a 5-year period. J Clin Microbiol 2006; 44: 3883–3886.
7. Rodriguez-Morales AJ, Rodriguez CN, Garcia A, Jimenez I, Pastran B,
Meijomil P. Surveillance analysis of decreasing susceptibility of Staphy-
lococcus aureus to vancomycin using a mathematical model. Int J Anti-
microb Agents 2007; 29: 607–609.
8. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN.
Characterization of vancomycin heteroresistant Staphylococcus aureus
(hVISA) from the Detroit Metropolitan area over a 22-year period
(1986–2007). J Clin Microbiol 2008; 46: 2950–2954.
9. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC
Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to
efﬁcacy of vancomycin for treatment of methicillin-resistant
Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–2402.
10. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A,
Moellering RC Jr. Accessory gene regulator group II polymorphism in
methicillin-resistant Staphylococcus aureus is predictive of failure of
vancomycin therapy. Clin Infect Dis 2004; 38: 1700–1705.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-
dose vancomycin therapy for methicillin-resistant Staphylococcus aureus
infections: efﬁcacy and toxicity. Arch Intern Med 2006; 166: 2138–2144.
12. Scottish audit of surgical mortality. Scottish audit of surgical mortal-
ity: summary report 2006 data. 2007.
13. Gupta R, Sinnett D, Carpenter R, Preece PE, Royle GT. Antibiotic
prophylaxis for post-operative wound infection in clean elective
breast surgery. Eur J Surg Oncol 2000; 26: 363–366.
14. Health Protection Agency. Third report of the mandatory surveillance of
surgical site infection in orthopaedic surgery. London: Health Protection
Agency, 2007.
15. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety
and efﬁcacy of daptomycin for the treatment of complicated skin and
skin-structure infections. Clin Infect Dis 2004; 38: 1673–1681.
16. Chang FY, MacDonald BB, Peacock JE Jr et al. A prospective multi-
center study of Staphylococcus aureus bacteremia: incidence of endo-
carditis, risk factors for mortality, and clinical impact of methicillin
resistance. Medicine (Baltimore) 2003; 82: 322–332.
17. Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identiﬁers of com-
plicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:
2066–2072.
18. Marra AR, Edmond MB, Forbes BA, Wenzel RP, Bearman GM. Time to
blood culture positivity as a predictor of clinical outcome of Staphylococ-
cus aureus bloodstream infection. J Clin Microbiol 2006; 44: 1342–1346.
19. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bac-
teremia: recurrence and the impact of antibiotic treatment in a pro-
spective multicenter study. Medicine (Baltimore) 2003; 82: 333–339.
20. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endo-
carditis in intravenous drug users. Antimicrob Agents Chemother 1990;
34: 1227–1231.
21. Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment
in patients with methicillin-susceptible Staphylococcus aureus bactere-
mia. Antimicrob Agents Chemother 2008; 52: 192–197.
CMI Stahl Positive outcomes for staphylococcal infections 31
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 6), 26–32
22. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin
or ﬁrst-generation cephalosporins for the treatment of hemodialysis-
dependent patients with methicillin-susceptible Staphylococcus aureus
bacteremia. Clin Infect Dis 2007; 44: 190–196.
23. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin
MIC and failure among patients with MRSA bacteremia treated with
vancomycin. Antimicrob Agents Chemother 2008; 52: 3315–3320.
24. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus
standard therapy for bacteremia and endocarditis caused by Staphylo-
coccus aureus. N Engl J Med 2006; 355: 653–665.
25. Ammerlaan H, Lightowler M, Marchant S, Strongman H, Bonten M.
Retrospective case study analysis of methicillin-resistant Staphylococ-
cus aureus treatment patterns in Europe. 9th International Symposium
of Modern Concepts in Endocarditis and Cardiovascular Infections,
14–17 June 2007, Heidelberg, Germany, Poster.
26. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis
of delayed antibiotic treatment for hospital-acquired Staphylococcus
aureus bacteremia. Clin Infect Dis 2003; 36: 1418–1423.
27. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The inﬂuence
of inadequate antimicrobial treatment of bloodstream infections on
patient outcomes in the ICU setting. Chest 2000; 118: 146–155.
28. Moellering RC Jr. Current treatment options for community-acquired
methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis
2008; 46: 1032–1037.
29. Lundstrom TS, Sobel JD. Antibiotics for gram-positive bacterial infec-
tions: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
Infect Dis Clin North Am 2004; 18: 651–668.
30. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomy-
cin serum concentrations with outcomes in patients with Gram-posi-
tive bacteremia. Pharmacotherapy 1995; 15: 85–91.
31. Aventis Pharma Ltd. Teicoplanin Summary of Product Characteristics.
2006.
32. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacoki-
net 2000; 39: 167–183.
33. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic
drug monitoring in critically ill patients: a retrospective study empha-
sizing the importance of a loading dose. J Antimicrob Chemother 2003;
51: 971–975.
34. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, War-
ren RE. Guidelines for the prophylaxis and treatment of methicillin-
resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimi-
crob Chemother 2006; 57: 589–608.
35. Novartis Europharm Ltd. Cubicin Summary of Product Characteristics.
2007.
36. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin phar-
macokinetics and safety following administration of escalating doses
once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:
1318–1323.
37. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus
on the activities of nafcillin, vancomycin, linezolid, and daptomycin,
alone and in combination with gentamicin, in an in vitro pharmacody-
namic model. Antimicrob Agents Chemother 2004; 48: 4665–4672.
38. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid
bactericidal activity of daptomycin against methicillin-resistant and
methicillin-susceptible Staphylococcus aureus peritonitis in mice as
measured with bioluminescent bacteria. Antimicrob Agents Chemother
2007; 51: 1787–1794.
39. Davis SL, McKinnon PS, Hall LM et al. Daptomycin versus vancomycin
for complicated skin and skin structure infections: clinical and eco-
nomic outcomes. Pharmacotherapy 2007; 27: 1611–1618.
40. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of
daptomycin by pulmonary surfactant: in vitro modeling and clinical
impact. J Infect Dis 2005; 191: 2149–2152.
41. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharma-
cokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:
1475–1480.
42. Boselli E, Breilh D, Rimmele T et al. Pharmacokinetics and intrapul-
monary concentrations of linezolid administered to critically ill
patients with ventilator-associated pneumonia. Crit Care Med 2005;
33: 1529–1533.
43. Cunha BA. Principles of antibiotic formulary selection for P&T com-
mittees. Part 5: The cost of antimicrobial therapy. Pharm Ther 2003;
28: 662–665.
44. Saloojee H, Steenhoff A. The health professional’s role in preventing
nosocomial infections. Postgrad Med J 2001; 77: 16–19.
45. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics
and tolerance of single- and multiple-dose oral or intravenous linezo-
lid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Che-
mother 2003; 51: 1239–1246.
46. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK.
Linezolid absolute bioavailability and the effect of food on oral bioa-
vailability. Biopharm Drug Dispos 2001; 22: 91–97.
47. Nathwani D, Barlow GD, Ajdukiewicz K et al. Cost-minimization ana-
lysis and audit of antibiotic management of bone and joint infections
with ambulatory teicoplanin, in-patient care or outpatient oral linezo-
lid therapy. J Antimicrob Chemother 2003; 51: 391–396.
48. Nathwani D, Li JZ, Balan DA et al. An economic evaluation of a Eur-
opean cohort from a multinational trial of linezolid versus teicoplanin
in serious Gram-positive bacterial infections: the importance of treat-
ment setting in evaluating treatment effects. Int J Antimicrob Agents
2004; 23: 315–324.
49. Esposito S, Leone S, Noviello S et al. Outpatient parenteral antibiotic
therapy for bone and joint infections: an Italian multicenter study. J
Chemother 2007; 19: 417–422.
50. Nathwani D. The management of skin and soft tissue infections: out-
patient parenteral antibiotic therapy in the United Kingdom. Che-
motherapy 2001; 47: 17–23.
51. Martone WJ, Lindﬁeld KC, Katz DE. Outpatient parenteral antibiotic
therapy with daptomycin: insights from a patient registry. Int J Clin
Pract 2008; 62: 1183–1187.
52. Rehm S, Campion M, Katz DE, Russo R, Boucher HW. Community-
based outpatient parenteral antimicrobial therapy (CoPAT) for Sta-
phylococcus aureus bacteraemia with or without infective endocarditis:
analysis of the randomized trial comparing daptomycin with standard
therapy. J Antimicrob Chemother 2009; 63: 1034–1042.
53. Ahmad QI, Mankowski M, Girish SR. Safety and tolerability of dapto-
mycin IV bolus injections in healthy adult volunteers. 46th Inter-
science Conference on Antimicrobial Agents and Chemotherapy
September 27–30, 2007, San Francisco, USA, Abstract A-1948.
54. Cubist Pharmaceuticals. Cubicin Prescribing Information. 2007.
55. Dandache P, Aronow WS, Sakoulas G. Clinical update on the diagno-
sis and treatment of bacterial endocarditis. Compr Ther 2007; 33:
192–207.
32 Clinical Microbiology and Infection, Volume 15, Supplement 6, December 2009 CMI
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 6), 26–32
